While meme stocks scream, this biotech’s whispering something much more profitable.

A quick read now could save you a late-to-the-party FOMO later.

From steady earnings to cleaner balance sheets, the market’s quieter corners are beginning to look a lot more interesting.

He called it a “renaissance.” No wonder ~40,000 people backed Amazon partner Miso Robotics. Miso’s kitchen robots fried 4M food baskets for brands like White Castle. In a $1T industry with 144% employee turnover, that’s big. So are Miso’s partnerships with NVIDIA and Uber. Initial units of its newest robot sold out in one week. Invest before Miso’s bonus shares change on 10/9.

_{This is a paid advertisement for Miso Robotics’ Regulation A offering. Please read the offering circular at invest.misorobotics.com.}

Don’t Let These Undervalued Stocks Slip Through Your Fingers!

We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.

👉 Click here to get stock picks by text and uncover the best value opportunities!

Biotech and Life Sciences

Qiagen NV (NYSE: QGEN) is back in the headlines after the Dutch regulator AFM dropped a voting rights update involving Bank of America’s holdings.

While the disclosure doesn’t move the earnings needle, it puts a spotlight on a company that’s silently become one of biotech’s better value propositions.

For a name that trades at a discount to many of its peers, institutional interest isn’t exactly surprising.

The company just proposed initiating a $0.25 per share annual dividend and approved a $500 million share repurchase program — strong signals that management believes cash returns matter now.

It’s a confident move that tells you Qiagen is ready to reward shareholders while keeping growth intact.

Underneath the regulatory noise, Qiagen’s fundamentals are starting to shine.

The FDA clearance for its QIA stat-Dx Rise platform opens fresh opportunities in the U.S. diagnostics market, while its QIAseq lineup continues to strengthen the company’s foothold in oncology and infectious disease testing.

It’s not a hyper-growth rocket, but that’s the appeal.

Qiagen’s solid margins, consistent product demand, and expanding precision medicine portfolio give it the kind of durability value investors like to see.

I’ll still rate it a Buy with a $53 target, and as the market’s hype cycles keep spinning, Qiagen might just be the steady hand worth holding.

Finance and Investment Management

Invesco Ltd’s (NYSE: IVZ) income investors are taking another look at its dividend power.

The stock’s yield has been catching attention as payouts continue to grow, even while much of Wall Street chases riskier growth stories.

That renewed interest isn’t surprising since Invesco has built a reputation for rewarding patience with consistent income and steady capital management.

The company just nudged its quarterly dividend up to $0.205 per share, another quiet signal that management’s confident in its cash flow.

The yield sits near 3.7%: strong, stable, and comfortably covered.

Between dividends and buybacks, Invesco’s handing income investors something rare in 2025: a payout story that doesn’t come with drama.

The firm’s fundamentals are solid, backed by more than $2 trillion in assets under management and a presence in over 20 countries.

Things look even more optimistic as earnings estimates tick higher, now confident in Invesco’s ability to sustain its performance in a choppy financial environment.

At a time when the market can’t decide if it wants excitement or safety, Invesco offers a bit of both.

Its dividend yield outpaces much of the sector, and the company’s long history of measured growth makes it a comfortable hold for investors who prefer income over speculation.

Sometimes, the quiet names deliver the loudest results.

Industrials and Packaging

Sealed Air Corp (NYSE: SEE) is in the spotlight because value investors are starting to circle back, arguing the packaging heavyweight still isn’t priced for its potential.

The market chatter centers on the idea that SEE’s fundamentals look sturdier than its valuation implies, with analysts flagging the company’s strong earnings outlook and leaner multiples compared to peers.

That kind of setup tends to attract patient money looking for an entry point before sentiment catches up.

The company’s balance sheet and cash generation remain the story here.

After navigating a stretch of sluggish demand, Sealed Air is stabilizing margins and fine-tuning operations to squeeze more profit out of every box, bag, and bubble.

I like that discipline, especially as SEE continues to generate consistent cash flow and a solid dividend yield without chasing risky expansion.

In a market obsessed with tech and speculation, Sealed Air offers a refreshing counterpoint: slow, steady, and still undervalued.

With earnings due in early November, all eyes are on whether the numbers confirm what we’ve been saying for weeks: that this stock might be ready for another run.

If you’re looking for something that actually earns its keep instead of selling a story, this is it. Sealed Air needs time.

The company’s doing what most don’t: delivering measurable progress while staying priced like it’s stuck in neutral.

When the market finally catches on, you’ll wish you bought it when it was still this quiet.

ICF International (ICFI: NASDAQ) is a value name that’s been steadily outperforming expectations.

The stock’s valuation setup appears appealing, trading at levels that suggest there’s still room for growth compared to its peers.

With a price-to-book that undercuts the industry and healthy cash flow metrics, investors are treating this as more than just another consulting play.

The story here is about steady fundamentals meeting a reasonable price tag, a combination that rarely goes unnoticed for long.

As Wall Street looks for value in a market that’s been chasing momentum, ICFI is one of those steady operators that might just reward those of us who are patient.

Encompass Health (EHC: NYSE): Investors are giving Encompass Health a second look — and it’s starting to feel less like a recovery play and more like a quiet operator that never really stumbled.

Earnings keep improving, margins are firming up, and the market still seems a step behind the diagnosis.

Analysts have been lifting their forecasts, signaling renewed confidence that profitability has room to improve without the stock getting ahead of itself.

What makes EHC interesting right now is the combination of consistency and value.

Its earnings revisions are trending higher, cash flow looks healthy, and the stock still trades at levels that leave upside on the table.

For investors looking for a dependable healthcare pick with potential to reward patience, EHC checks the right boxes.

Exelixis (EXEL: NASDAQ): Looks like traders have rediscovered an old biotech tune, and the momentum crowd’s circling like sharks that just smelled earnings.

This biotech’s finally found its rhythm, and the beat’s getting louder.

The stock has been flexing steady price strength, backed by rising earnings estimates and consistent performance in a tough sector.

Analysts have nudged forecasts higher, showing confidence in the company’s ability to turn clinical progress into real profits.

What makes EXEL interesting now is that it’s balancing scientific depth with market momentum.

Investors like that rare combo of reliable fundamentals paired with a stock that’s been silently gaining traction.

With solid demand trends and analysts raising the bar, EXEL stands out as a momentum play that’s built on more than just sentiment.

It’s biotech with a backbone, and investors are paying attention.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you'd like us to dig into.

Best Regards,
—Noah Zelvis
Undervalued Edge